Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte initiated with a Neutral at UBS
- Incyte says Phase 3 inMIND trial met primary endpoint of PFS
- Incyte announces results from Phase 3 trial evaluating retifanlimab in NSCLC
- Incyte gets FDA orphan designation for treatment of nodal marginal zone lymphoma
- Biotech Alert: Searches spiking for these stocks today